Table 5 Changes in safety values of subjects after 12–14 weeks on placebo or α-CD either measured by conventional biochemistry methods or by NMR (mean ± SEM)
From: Randomized double blind clinical trial on the effect of oral α-cyclodextrin on serum lipids
Safety parameters | Placebo | α-CD | p |
|---|---|---|---|
CRP HS (<3.0 mg/L) | 2.1 ± 0.5 | 2.0 ± 0.4 | 0.8 |
AST (9–34 U/L) | 20.6 ± 0.7 | 19.2 ± 1.1 | 0.1 |
ALT (6–41 U/L) | 28.6 ± 1.4 | 26.9 ± 1.1 | 0.08 |
TSH (0.40 − 4.00 mcIU/mL) | 1.9 ± 0.1 | 1.9 ± 0.1 | 0.7 |
Urea (8–22 mg/dL) | 13.3 ± 0.5 | 12.9 ± 0.5 | 0.4 |
Creatinine (0.56 − 1.16 mg/dL) | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.8 |
Albumin (3.5 − 5.2 g/dL) | 4.2 ± 0.1 | 4.2 ± 0.1 | 0.8 |
Alk Phosp (35–105 U/L) | 57.5 ± 1.8 | 57.5 ± 1.7 | 0.9 |
Vitamin A (24–85 mcg/dL) | 55.9 ± 1.6 | 55.4 ± 1.6 | 0.6 |
Vitamin D (18–78 pg/mL) | 52.3 ± 1.6 | 53.9 ± 1.9 | 0.3 |
Vitamin E (5.0 − 19.0 mg/L) | 10.8 ± 0.4 | 10.8 ± 0.3 | 0.9 |
RBC (3.93 − 5.22 M/uL) | 4.6 ± 0.1 | 4.6 ± 0.1 | 0.4 |
WBC (3.98 − 10.04 K/uL) | 5.5 ± 0.1 | 5.4 ± 0.1 | 0.4 |